Provention Bio, which is developing in-licensed therapies for autoimmune and inflammatory diseases, filed on Wednesday with the SEC to raise a minimum of $40 million and a maximum of $50 million in an initial public offering.
The deal is being marketed on a best efforts basis, and will therefore be excluded from Renaissance Capital's IPO stats.
The Oldwick, NJ-based company was founded in 2016 and plans to list on the Nasdaq under the symbol PRVB. Provention Bio filed confidentially on February 12, 2018. MDB Capital Group is the sole bookrunner on the deal. No pricing terms were disclosed.
